Orchestra BioMed Holdings, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $33.5M | $2.6M | $2.8M | $3.5M | — |
| Operating income | -$51.8M | -$64.3M | -$51.5M | -$32.7M | -$394,756 |
| Cost of revenue | $190,000 | $204,000 | $186,000 | $211,000 | — |
| Cash from operations | -$49.0M | -$50.6M | -$46.1M | -$29.3M | -$272,362 |
| Capital expenditure | $489,000 | $289,000 | $78,000 | $591,000 | — |
| Free cash flow | -$49.5M | -$50.8M | -$46.2M | -$29.9M | — |
| Impairments | $0 | $0 | $0 | $5.0M | $5.0M |
| Total assets | $114.9M | $76.2M | $95.2M | $95.6M | $161.8M |
| Total liabilities | $51.5M | $43.2M | $27.2M | $43.0M | $5.8M |
Shares outstanding 59.9M · Free float 58.1%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.